Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17909865rdf:typepubmed:Citationlld:pubmed
pubmed-article:17909865lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0393022lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0796392lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0443286lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0032893lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0995188lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C1516732lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0541653lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C1514923lld:lifeskim
pubmed-article:17909865lifeskim:mentionsumls-concept:C0686907lld:lifeskim
pubmed-article:17909865pubmed:issue4lld:pubmed
pubmed-article:17909865pubmed:dateCreated2008-3-21lld:pubmed
pubmed-article:17909865pubmed:abstractTextMonoclonal antibody (MoAb) treatments can result in severe infusion reactions. Managing infusion reactions in the outpatient setting introduces clinical and resource challenges for patients and providers, but there is little information regarding prevention, management, or outcomes of severe infusion reactions. This study represents one of the first attempts to describe the clinical consequences of severe infusion reactions associated with MoAb treatment.lld:pubmed
pubmed-article:17909865pubmed:languageenglld:pubmed
pubmed-article:17909865pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:citationSubsetIMlld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17909865pubmed:statusMEDLINElld:pubmed
pubmed-article:17909865pubmed:monthAprlld:pubmed
pubmed-article:17909865pubmed:issn0941-4355lld:pubmed
pubmed-article:17909865pubmed:authorpubmed-author:StepanskiEdwa...lld:pubmed
pubmed-article:17909865pubmed:authorpubmed-author:SchwartzbergL...lld:pubmed
pubmed-article:17909865pubmed:authorpubmed-author:FortnerBarry...lld:pubmed
pubmed-article:17909865pubmed:authorpubmed-author:HoutsArthur...lld:pubmed
pubmed-article:17909865pubmed:issnTypePrintlld:pubmed
pubmed-article:17909865pubmed:volume16lld:pubmed
pubmed-article:17909865pubmed:ownerNLMlld:pubmed
pubmed-article:17909865pubmed:authorsCompleteYlld:pubmed
pubmed-article:17909865pubmed:pagination393-8lld:pubmed
pubmed-article:17909865pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:meshHeadingpubmed-meshheading:17909865...lld:pubmed
pubmed-article:17909865pubmed:year2008lld:pubmed
pubmed-article:17909865pubmed:articleTitleRetrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.lld:pubmed
pubmed-article:17909865pubmed:affiliationAccelerated Community Oncology Research Network, Memphis, TN 38138, USA. lschwartzberg@sosacorn.comlld:pubmed
pubmed-article:17909865pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17909865pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17909865lld:pubmed